Key result
Fractional excretion of urea (FeUrea) significantly correlated with improvement of renal function in patients with type 1 cardiorenal syndrome (P=0.00001).
Why the study?
Does fractional excretion of urea predict improvement in renal function and survival in patients with type 1 cardiorenal syndrome?
Observational (n=116)
Does fractional excretion of urea predict improvement in renal function and survival in patients with type 1 cardiorenal syndrome?
p-value: p=0.00001
Fractional excretion of urea is a significant predictor of renal function improvement in patients with type 1 cardiorenal syndrome.
May aid renal recovery assessment in type 1 cardiorenal syndrome; leaves open whether it guides therapy pending prospective validation.
The fractional excretion of urea is a useful tool to evaluate renal function in oliguric states; however, it remains unexplored in nonoliguric states. We evaluated its use to predict responses in patients with type 1 cardiorenal syndrome. This was a prospective observational study of 116 patients with type 1 cardiorenal syndrome referred over a 4-year period. Fractional excretion of urea and sodium, ejection fraction, mean arterial pressure, age, sex, diabetes, brain natriuretic peptide (BNP), serum sodium and blood urea nitrogen were analyzed for effects upon serum creatinine and survival. Improvement of renal function correlated most significantly with FeUrea (P = 0.00001) followed by the FeNa (P = 0.005) but no other variable studied reached significance. Survival was best predicted by improvement of the serum creatinine at 24 h (P = 0.005) and 7 days after all inotropes were stopped (P = 0.001). A limitation of this study is that it cannot be extrapolated to all cardiorenal syndrome patients other than type 1. Also, the study was not randomized and those with potentially worse disease have had worse outcomes due merely to worse underlying disease. The success of the FeUrea may possibly be related to interference of dobutamine on creatinine levels. Despite being a nonoliguric state, the FeUrea appears to provide insight to those patients with type 1 cardiorenal syndrome whose renal function (as measured by serum creatinine) and survival might improve.
No takes yet. Share an insight, caveat, or question.
Diskin et al. (2018) conducted an observational in Type 1 cardiorenal syndrome (n=116). Fractional excretion of urea (FeUrea) was evaluated on Improvement of renal function (p=0.00001). Fractional excretion of urea (FeUrea) significantly correlated with improvement of renal function in patients with type 1 cardiorenal syndrome (P=0.00001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: